Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanoparticle reduces targeted cancer drug's toxicity

The polymeric nanoparticle Accurin encapsulates the clinical candidate AZD2811, an Aurora B kinase inhibitor. This material relates to a paper that appeared in the Feb. 10, 2016 issue of Science Translational Medicine, published by AAAS. The paper, by S. Ashton at institution in location, and colleagues was titled, "Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo."
CREDIT: Ashton et al., Science Translational Medicine (2016)
The polymeric nanoparticle Accurin encapsulates the clinical candidate AZD2811, an Aurora B kinase inhibitor. This material relates to a paper that appeared in the Feb. 10, 2016 issue of Science Translational Medicine, published by AAAS. The paper, by S. Ashton at institution in location, and colleagues was titled, "Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo."

CREDIT: Ashton et al., Science Translational Medicine (2016)

Abstract:
In one of the first efforts to date to apply nanotechnology to targeted cancer therapeutics, researchers have created a nanoparticle formulation of a cancer drug that is both effective and nontoxic -- qualities harder to achieve with the free drug.

Nanoparticle reduces targeted cancer drug's toxicity

Washington, DC | Posted on February 11th, 2016

Their nanoparticle creation releases the potent but toxic targeted cancer drug directly to tumors, while sparing healthy tissue. The findings in rodents with human tumors have helped launch clinical trials of the nanoparticle-encapsulated version of the drug, which are currently underway. Aurora kinase inhibitors are molecularly targeted agents that disrupt cancer's cell cycle. While effective, the inhibitors have proven highly toxic to patients and have stalled in late-stage trials. Development of several other targeted cancer drugs has been abandoned because of unacceptable toxicity. To improve drug safety and efficacy, Susan Ashton and colleagues designed polymeric nanoparticles called Accurins to deliver an Aurora kinase B inhibitor currently in clinical trials. The nanoparticle formulation used ion pairing to efficiently encapsulate and control the release of the drug. In colorectal tumor-bearing rats and mice with diffuse large B cell lymphoma, the nanoparticles accumulated specifically in tumors, where they slowly released the drug to cancer cells. Compared to the free drug, the nanoparticle-encapsulated inhibitor blocked tumor growth more effectively at one half the drug dose and caused fewer side effects in the rodents. A related Focus by David Bearss offers more insights on how Accurin nanoparticles may help enhance the safety and antitumor activity of Aurora kinase inhibitors and other molecularly targeted drugs.

####

For more information, please click here

Contacts:
Natasha Pinol

202-326-7088

Copyright © American Association for the Advancement of Science

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

RELATED JOURNAL ARTICLE:

Related News Press

News and information

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Iran World’s Second Largest Producer of Nano-Catalysts October 17th, 2018

Iran Unveils Its First Homegrown 3D Nano Printer October 17th, 2018

Fat-Repellent Nanolayers Can Make Oven Cleaning Easier October 17th, 2018

Cancer

Nano Pharmaceutical Developed to Target Cancer Cells October 10th, 2018

Scientists use nanoparticles to improve chemotherapy response, boost anti-tumor immunity: U of T scientists use nanoparticles to improve chemotherapy response and boost anti-tumor immunity in breast cancer October 2nd, 2018

Rice U. lab probes molecular limit of plasmonics: Optical effect detailed in organic molecules with fewer than 50 atoms September 5th, 2018

Polymer antibodies efficiently target and eliminate cancer cells August 27th, 2018

Nanomedicine

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics October 17th, 2018

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Discoveries

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Researchers quickly harvest 2-D materials, bringing them closer to commercialization: Efficient method for making single-atom-thick, wafer-scale materials opens up opportunities in flexible electronics October 12th, 2018

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

High-performance self-assembled catalyst for SOFC October 12th, 2018

Announcements

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics October 17th, 2018

Iran Produces Cooling Fabrics Using Nanotechnology October 17th, 2018

Iran World’s Second Largest Producer of Nano-Catalysts October 17th, 2018

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

High-performance self-assembled catalyst for SOFC October 12th, 2018

Nanobiotechnology

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics October 17th, 2018

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project